Unlike the results seen with mutations at the palmitoylation site of N-RAS (i.e., palmitoylation-defective mutant N-RASG12D/C181S), palmitoylation-defective K-RAS4A could still induce leukaemia in mice (Zhao et al., 2015). Here, KRAS is linked to leukemia.